help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teng, C. S.
Right arrow Articles by Yeung, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teng, C. S.
Right arrow Articles by Yeung, R. T.

Journal of Clinical Endocrinology & Metabolism, Vol 50, 144-147, Copyright © 1980 by Endocrine Society

ARTICLES

Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study

CS Teng and RT Yeung

Thyroid-stimulating antibodies (TSAb) were found in 51 patients (83.6%) with untreated Graves' disease. The mean TSAb index reached the normal level after 6 months of antithyroid drug therapy. In 9 patients (14.8%), TSAb remained persistently positive during and after antithyroid drug therapy, and relapse occurred in all. In 42 patients (68.8%), TSAb indices gradually returned to the normal range after drug treatment was started; in 38% of these, remission was maintained after treatment was stopped, in another 40.5%, relapse occurred when they were TSAb-positive, and the remaining 21.5% relapsed despite return of TSAb indices to the normal range. A positive TSAb index at the end of drug treatment was a useful indicator in predicting subsequent relapse because, with 1 exception, all patients who were still TSAb positive at drug withdrawal relapsed subsequently.


This article has been cited by other articles:


Home page
 NEJMHome page
D. S. Cooper
Antithyroid Drugs
N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. S. Brokken, J. W. C. Scheenhart, W. M. Wiersinga, and M. F. Prummel
Suppression of Serum TSH by Graves' Ig: Evidence for a Functional Pituitary TSH Receptor
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4814 - 4817.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. F. Davies
Thyroid-Stimulating Antibodies Predict Hyperthyroidisma
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3777 - 3781.
[Full Text]

Home page
 NEJMHome page
J. A. Franklyn
The Management of Hyperthyroidism
N. Engl. J. Med., June 16, 1994; 330(24): 1731 - 1738.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society